Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits following the termination of its collaboration with Novo Nordisk due to concerns over deceptive marketing practices related to the weight loss drug Wegovy® [1][2][4]. Group 1: Lawsuits and Allegations - The lawsuits, filed in Northern California, seek to represent investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3]. - Allegations include that Hims & Hers made false and misleading statements and failed to disclose critical information regarding the safety and legality of its marketing practices [4][5]. - The complaints specifically mention that the company engaged in deceptive promotion and selling of knockoff versions of Wegovy®, which posed risks to patient safety and jeopardized its collaboration with Novo Nordisk [4][5]. Group 2: Impact of Novo Nordisk's Decision - Novo Nordisk announced the termination of its collaboration with Hims & Hers on June 23, 2025, citing concerns over illegal mass compounding and deceptive marketing practices [2][5]. - The announcement led to a significant 30% drop in the share price of Hims & Hers [2]. - Novo Nordisk emphasized that Hims & Hers failed to comply with legal standards regarding the sale of compounded drugs, which raised serious patient safety concerns [5]. Group 3: Investigation and Investor Actions - Hagens Berman, a national shareholders rights firm, is investigating the legal claims and encourages affected investors to report their losses [3][6]. - The firm is also seeking information from individuals who may assist in the investigation, highlighting the potential for whistleblower rewards under the SEC Whistleblower program [6].

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific allegations include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 2: Participation Information - Investors who purchased Hims common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Here are some stocks on the move. There obviously are many today. Hims and Hers is pacing for its worst week ever.You flag this to our our crew. It's something that I've never seen before. So, the stock started this week with a 35% crash because they had a joint venture with um Novo Nordisk to sell legitimate ver I shouldn't say legitimate to sell branded version of Wevy versus the compounded version that they've been selling.and then Novo Nordisk after a month put out a press release basically accusing the ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive. For more information, submit a form at Hms & Hers Health, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or c ...

Core Viewpoint - Hims & Hers Health, Inc. (HIMS) has experienced a significant decline of 22.4% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - HIMS has an RSI reading of 29.06, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium [5]. - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify potential reversal points, making it a useful tool for investors seeking entry opportunities [3]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding HIMS, with a 0.6% increase in the consensus EPS estimate over the last 30 days, indicating a positive outlook for earnings [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term, supporting the case for a potential stock rebound [7]. - HIMS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further indicating a favorable outlook for the stock [8].

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential violations of federal securities laws following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and safety risks associated with its products [1][3]. Group 1: Company Overview - Hims & Hers is a telehealth company that offers online consultations with licensed healthcare professionals, prescription medications, and wellness products [2]. - The company entered a "long-term collaboration" with Novo Nordisk to sell the weight loss drug Wegovy [2]. Group 2: Recent Developments - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing accusations of "deceptive marketing" and the sale of illegitimate versions of Wegovy [3]. - Following the announcement, Hims & Hers' stock price dropped by $22.25 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.97 on June 23, 2025 [3]. Group 3: Legal Implications - Bleichmar Fonti & Auld LLP is investigating Hims & Hers for potential legal actions related to the stock decline and allegations of misconduct [1][4]. - Investors in Hims & Hers are encouraged to seek legal options and submit their information to the law firm for potential representation [4]. Group 4: Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, with notable recoveries in past cases [5].

Core Viewpoint - Novo Nordisk has ended its distribution partnership with Hims & Hers Health over the latter's sale of compounded drugs, specifically the weight loss therapy Wegovy (semaglutide), which led to a significant drop in Hims & Hers' stock price [1][2] Group 1: Company Actions and Reactions - Novo Nordisk accused Hims & Hers of not adhering to legal standards and allegedly selling compounded drugs under the guise of "personalization" [1] - Hims & Hers CEO Andrew Dudum stated that the company will continue to offer affordable compounded Wegovy despite the termination of the partnership, emphasizing the company's commitment to customer interests [1][2] - Dudum highlighted that Novo Nordisk pressured Hims & Hers to direct patients towards the branded Wegovy, regardless of clinical appropriateness for patients [2] Group 2: Regulatory Context - Novo Nordisk's executive, Ludovic Helfgott, mentioned that there was an agreement to stop the large-scale production of compounded drugs, which was not honored by Hims & Hers [2] - According to U.S. regulations, pharmaceutical companies are allowed to produce compounded drugs in large quantities if there is a drug shortage, which was the case for Wegovy until it was removed from the shortage list by the FDA in April [2]

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ to ...

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly violating federal securities laws by making false and misleading statements regarding the company's business and operations [1][2]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Hims & Hers made false statements about a collaboration with Novo Nordisk that would ensure continued access to the weight-loss drug Wegovy for its subscribers [2]. - It is alleged that Hims & Hers misrepresented that Novo approved its offerings of compounded semaglutide products under a "personalization" exception [2]. - The suit contends that Hims & Hers falsely indicated that branded Wegovy would be available alongside compounded semaglutide options, thereby misleading investors about user choice [2]. - Positive statements regarding the partnership with Novo and ongoing access to Wegovy were also allegedly made, which contributed to the decline in the company's stock value [2]. Group 2: Legal Proceedings - The lawsuit was filed in the Northern District of California and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05321 (N.D. Cal.) [3]. - The class action is on behalf of all individuals who purchased Hims & Hers common stock between April 29, 2025, and June 23, 2025 [3]. Group 3: Class Member Information - Investors who acquired Hims & Hers stock during the specified class period may seek to be appointed as lead plaintiffs, with a deadline to do so by August 25, 2025 [4]. - It is noted that investors do not need to be lead plaintiffs to participate in any potential recovery from the lawsuit [5].

Core Viewpoint - Hims & Hers Health, Inc. experienced a significant share price drop of over 30% following the termination of its collaboration with Novo Nordisk due to concerns regarding sales practices and marketing of the weight loss drug Wegovy® [1][4]. Company Summary - Hims & Hers Health, Inc. had previously partnered with Novo Nordisk to provide access to Wegovy®, which is FDA-approved for obesity treatment, through its platform [3]. - The partnership was short-lived, as Novo Nordisk cited "illegal mass compounding and deceptive marketing" as reasons for the termination [4]. - Hims & Hers had previously assured investors of its regulatory compliance, claiming it was not bypassing the regulatory process [2]. Investigation Summary - Hagens Berman, a national shareholders rights firm, has initiated an investigation into potential violations of securities laws by Hims & Hers, urging affected investors to report their losses [2]. - The investigation will focus on whether Hims & Hers misled investors regarding the marketing of potentially unsafe versions of Wegovy® [4].